Mechanical Alternatives to the Human Heart: Intracorporeal Assist Systems and Total Artificial Heart

Jacob Lavee MD and Yoav Paz MD
Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel

Key words: ventricular assist device, artificial heart, heart transplantation, congestive heart failure

In the previous part of this review [1] we outlined the currently available paracorporeal assist systems used in patients terminally ill with congestive heart failure. Since all these systems require continuous hospitalization of the patient due to the cumbersome bedside hardware, intracorporeal assist systems have been developed that enable the patient’s discharge while on the device. This part of the review will outline the currently available intracorporeal assist systems and the total artificial heart.

There are currently two intracorporeal assist systems approved for use: the HeartMate LVAD (Thoratec Corporation, formerly Thermo Cardiosystems Inc., Woboum, MA, USA) and the Novacor LVAD (WorldHeart, Ottawa, Ontario, Canada)

The HeartMate LVAD

The HeartMate LVAD is an implantable pulsatile blood pump that is available in pneumatically driven (implantable pneumatic) or electrically powered (vented electric) models. More than 2,300 devices have been implanted since 1986, establishing it as one of the major cornerstones in long-term, often out-of-hospital, left ventricular assistance.

Both models of the HeartMate are fabricated from sintered titanium and house a flexible, textured, polyurethane diaphragm bounded to a rigid pusher-plate. In the IP model the pusher-plate is actuated pneumatically from a portable external console, while in the VE model the pusher-plate is actuated by a low-speed torque motor that drives a pair of nested helical cams. A single, two channeled, velour-covered drive-line leads from the implanted LVAD, through the skin, to the external environment [Figure 1]. In the IP model one of the channels contains an electric cable conveying performance data to the bedside console, while the other provides for the air transfer. In the VE model one of the drive-line channels contains the electric cable leading from the portable battery pack to the motor, while the other acts as an air vent allowing air transfer in and out of the motor chamber in order to maintain it near atmospheric conditions. A unique feature of the HeartMate is the design of the blood-contacting parts, whereby the titanium housing incorporates titanium microspheres and the flexible diaphragm is covered with textured polyurethane, both promoting the adherence of cellular blood elements and the formation of a pseudo-intimal layer. This configuration assures an exceptionally low thromboembolic risk with this device [2]. Both models of the HeartMate are equipped with inflow and outflow porcine xenograft valves. Both models can generate a maximum stroke volume of 85 ml and a maximum pump output of 11 L/min, and they are usually operated in an automatic mode whereby the ejection cycle begins only after the pump is at least 90% filled. The VE model with its wearable two battery pack provides patients with 6–8 hours of untethered activity.

Most HeartMate LVADs were implanted in a preperitoneal pocket behind the left rectus abdominis posterior sheath. Some centers prefer the intraabdominal placement; however internal organ erosions, bowel obstruction, and intraabdominal adhesions have rendered this approach less favorable. Following preparation of the preperitoneal pocket, the patient is placed on cardiopulmonary bypass, and an apical silicone cuff is sewn to the left ventricular apex that has been cored out by a circular coring knife. The LVAD is inserted into its pocket, tunneling its drive-line subcutaneously to exit in the right mid to upper quadrant.

Figure 1. Schematic illustration of the implanted HeartMate VE LVAD. (With permission from Thermo Cardiosystems, Inc., Woboum, MA, USA.)

IP = implantable pneumatic
VE = vented electric
area. The pump inflow cannula is then brought through the diaphragm and inserted through the apical cuff. The outflow Dacron graft is anastomosed to the right lateral surface of the ascending aorta, and following meticulous de-airing maneuvers the outflow graft is screwed to the pump outflow port [Figure 1]. As cardiopulmonary bypass is weaned, the device is activated first in a slow fixed mode, to be replaced by automatic mode when the hemodynamic status stabilizes.

Patients assisted by the HeartMate LVAD are maintained on aspirin alone, with no need for anticoagulation. Patients implanted with the HeartMate VE experience a significant improvement in quality of life during LVAD support, as many of them are frequently discharged from the hospital while on the device and can return to their families and work or school activities [Figure 2].

The HeartMate LVAD is usually used as a bridge-to-transplantation device. As such, the presence of any contraindication to transplantation negates candidacy for long-term support. The incidence of right heart failure and the need for temporary RVAD assistance following HeartMate LVAD implantation have been greatly reduced since the routine introduction of inhaled nitric oxide [3]. Preoperative low pulmonary artery pressure and low right ventricular stroke work index have been shown to be significant risk factors for RVAD use [4]. The following predictive factors have been shown [5] to be associated with perioperative mortality: oliguria (urine output < 30 ml), elevated central venous pressure (>16 mmHg), the need for mechanical ventilation, elevated prothrombin time (>16 sec), and prior mediastinal operation.

According to the last reported data from the Thermo Cardiosystems Worldwide Registry in September 2000, 65% of the 2,265 patients implanted with the HeartMate IP or VE have survived implantation; 63% were transplanted and in 2% the native heart recovered and the device was explanted. Infections, the achilles heel of all devices, have always been a major cause for failure with this device [6,7]. More than 250 patients were supported with the device for more than 6 months, and more than 60 patients were supported for more than one year. Some patients were supported for more than 2 years, which sparked interest in the use of the device as an alternative to transplantation, leading to the REMATCH trial [8]. The multicenter REMATCH trial (Randomized Evaluation of Mechanical Assist Treatment for Congestive Heart failure) compared the outcomes of 68 non-transplant candidates in New York Heart Association class IV heart failure supported with the HeartMate VE LVAD to 61 similar patients on current maximal medical therapy. The one year survival rates were 52% in the device group and 29% in the medical therapy group ($P = 0.002$).

The Novacor LVAD

The Novacor LVAD was the first electrically powered implantable assist device, and since its first human use at the Stanford University Medical Center in 1984 more than 1,000 patients were supported by it worldwide.

The Novacor LVAD blood pump is made of a smooth polyurethane sac actuated by a pulsed solenoid energy converter motor, which activates two identical pivoted pusher-plates. Inflow and outflow porcine valves maintain unidirectional blood flow through knitted, gelatin-sealed Vascutek inflow and outflow grafts. A percutaneous vent tube, containing power and control leads, connects the internalized blood pump to an extracorporeal electronic control and wearable batteries.

The implantation technique of the Novacor LVAD is very similar to that of the HeartMate [Figure 3], with the pump implanted usually in a preperitoneal pocket behind the left rectus muscle. The device's vent tube is tunneled subcutaneously to be exteriorized midway between the right costal margin and the anterosuperior iliac crest. Similar to the experience with the HeartMate LVAD, the need for temporary RVAD assistance following implantation of the Novacor LVAD has been greatly decreased to less than 6% since the introduction of inhaled nitric oxide [3]. Patients assisted by the Novacor LVAD are usually maintained on warfarin and aspirin. Novacor-assisted patients can be discharged from the hospital and return home to normal daily activities, allowing for a better quality of life while waiting for transplantation.

The recent results of the global experience with the Novacor LVAD, comprising 1,040 implants, show that in 93.4% of the patients the device was used as a bridge to transplant, in 4.3% as a bridge to recovery and in 2.3% as an alternative to transplant. Half of the patients were supported...
for more than 6 months, with mean support duration of 254 days. The longest support duration was more than 4 years — the longest time that any recipient has lived with continuous support from a heart assist device. A high incidence of embolic stroke — ranging from 21% with the previously used, woven unsupported Cooley grafts, to 12% with the more recently used, knitted, gelatin-sealed, supported Vascutek grafts — has been one of the major hallmarks of the Novacor LVAD [9,10]. In contrast, an excellent reliability record with a pump replacement incidence of only 0.8% has been one of its virtues. In a U.S. multicenter bridge-to-transplant study that included 156 Novacor LVAD recipients, 73% were successfully bridged to transplant [9]. In a single center (Deutsches Herzzentrum in Berlin) that used the Novacor LVAD as a bridge to recovery in 23 patients, stable cardiac recovery occurred in 13 patients for 3–49 months; 7 patients had recurrent cardiac failure after 4–24 months, transplantation was performed in 6 of them and one died while on the waiting list; and 3 patients died of non-cardiac causes within 4 months and 3 days after removal of the assist device [11]. To date, the data are insufficient to determine the viability of this form of therapy.

The CardioWest Total Artificial Heart

The total artificial heart was first used at the University of Utah in 1982 and was known as the Jarvik-7 TAH [12]; it continued for several years as the Symbion TAH until its use was halted in 1991 following loss of its investigational device exemption due to a high incidence of morbidity and mortality. Since 1993 a new investigational device exemption study was begun at the University Medical Center in Tucson, Arizona with the now-called CardioWest TAH (CardioWest Technologies, Inc.) and a multicenter trial was undertaken.

The CardioWest TAH is a pneumatically driven biventricular pump that is implanted in the orthotopic position. It consists of two ventricles connected to the respective native atria and great vessels. A velour-covered air drive-line passes from each of the ventricles transcutaneously to a large console that pressurizes air and monitors pump function (Figure 4). Each of the two ventricles consists of a spherical polyurethane chamber, half of it immobile and anchored to the chamber rigid wall, and the other half a mobile four-layered diaphragm. Pulses of air pressure from the console push the diaphragm and thus blood is ejected from the chamber. Vacuum added to the device in diastole improves ventricular filling at low venous pressures. Medtronic-Hall mechanical valves located at the inflow and outflow of each of the chambers provide for unidirectional blood flow. Specialized cuffs anastomosed to the native atria allow for quick connection of the ventricles, while Dacron outflow grafts provide connective tissue to the great vessels. The maximal blood volume of each of the chambers is 70 ml, and the cardiac output is generally between 6 and 8 L/min.

Due to the considerable size of the implanted two chambers of the CardioWest TAH, adherence to stringent fitting criteria guidelines must be followed carefully to prevent a poor outcome. Patients with a body surface area less than 1.7 m², thin chest, or cardiothoracic ratio less than 0.5 are at increased risk of inferior vena cava or left pulmonary vein compression. The implantation technique, as recently described [13], starts with total cardiectomy, leaving behind a maximal length of the great vessels and the two atria, which are cut at the atrioventricular groove. The atrial quick connector cuffs are anastomosed to each of the two native atria, followed by end-to-end anastomosis of the two outflow grafts to the aorta and pulmonary artery. Next, the atrial connector of the left ventricle is snapped on to the left atrial quick connector, the ventricle is filled with saline and the aortic connection is made. A similar approach is followed with the right ventricle. After de-airing maneuvers, console pumping is started and the patient is rapidly weaned off cardiopulmonary bypass. The device’s two air drive-lines are tunneled to the left epigastrum.

Patients on the CardioWest TAH are maintained on warfarin, aspirin, dipyrindamole and pentoxyphillin. The need for these patients to be permanently tethered to a large console makes out-of-hospital existence with this device impractical, however walking within the confines of the hospital is possible for short periods with battery power and air tank backup of the console.

The current indication for using the CardioWest TAH is as a bridge to transplant in patients with rapid decompensation involving biventricular failure that is unresponsive to maximal medical therapy [14].

The results of a U.S. national trial of the CardioWest TAH [14] have shown that of 27 patients supported for an average of 52 days (range 12–186 days), 93% underwent heart transplantation and 89% were discharged home. The most common source of morbidity was infection, occurring in 90% of the patients but only in 10% was it considered severe. No serious neurologic events causing death occurred, however non-serious events included nine transient ischemic attacks, three seizures, two episodes of impaired state of consciousness, one retinal hemorrhage, one retinal embolus and one cerebrovascular accident. Internationally, there were 175 implants with a 65% transplantation rate and 88% discharge rate for transplanted patients [15].

Summary

The currently available intracorporeal assist systems and total artificial heart provide long-term support for patients terminally ill with congestive heart failure, often in an out-of-hospital environ-

---

TAH = total artificial heart

---

---
ment. While they are currently widely used mainly as a long-term bridge to heart transplantation, their inherent risks of infection or stroke are prompting interest in future devices that will be smaller, fully implantable and hopefully stroke-free. These devices will be described in the last part of this review.

References

Correspondence: Dr. J. Lavee, Director, Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer 52621, Israel.
Phone: (972-3) 530-2225, Cell 058-546271
Fax: (972-3) 535-2777
email: jaylavee@netvision.net.il

---

**Capsule**

**Inhibition of matrix metalloproteinases, hepatitis and anti-tumor therapy**

Acute and fulminant liver failure induced by viral hepatitis, alcohol or other hepatotoxic drugs, are associated with tumor necrosis factor (TNF) production. In a mouse model of lethal hepatitis induced by TNF, apoptosis and necrosis of hepatocytes, but also lethality, hypothermia and influx of leukocytes into the liver, are prevented by a broad-spectrum matrix metalloproteinase (MMP) inhibitor, BB-94. Mice deficient in MMP-2, MMP-3 or MMP-9 had lower levels of apoptosis and necrosis of hepatocytes, and better survival. Wielockx et al. found induction of MMP-9 activity and fibronectin degradation. Their findings suggest that several MMPs play a critical role in acute fulminant hepatitis by degrading the extracellular matrix and allowing massive leukocyte influx in the liver. BB-94 also prevented lethality in TNF/interferon therapy in tumor-bearing mice. A broad-spectrum MMP inhibitor may be potentially useful for the treatment of patients with acute and perhaps chronic liver failure, and in cancer therapies using inflammatory cytokines.

---

**Capsule**

**Gut cells and the nervous system**

The epithelium of the mouse small intestine contains three secretory cell types (the goblet cells, enteroendocrine cells, and Paneth cells) and absorptive enterocytes. Yang et al. examined whether the factor Math1, which is found in the intestine and reported to be necessary for cell fate determination in the central nervous system, is involved in gut cell determination. In mice that lack functional Math1, the secretory cells failed to differentiate and the progenitors remained in the proliferating stage. However, the loss of Math1 did not affect the enterocytes. Science 2001;294:2155